269 results about "Anti inflammatories" patented technology

Methods and compositions for treating or preventing, the occurrence of senile dementia of the Alzheimer's type, mild cognitive impairment, or other conditions arising from reduced neuronal metabolism and leading to lessened cognitive function are described. In a preferred embodiment the administration of triglycerides or fatty acids with chain lengths between 5 and 12, to said patient at a level to produce an improvement in cognitive ability, and a therapeutic agent selected from the group consisting of anti-Alzheimer's agents, anti-diabetic agents, agents capable of increasing utilization of lipids, anti-atherosclerotic agents, anti-hypertensive agents, anti-inflammatory agents, anti-obesity agents, and combinations thereof. Preferred therapeutic agents include donepezil, rivastigmine, galantamine, and memantine.

A medical device comprising a supporting structure capable of including or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient may include one or more therapeutic agents or substances, with the carrier including a coating on the surface thereof, and the coating including the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. Drugs that are suitable for use in this invention include, but are not limited to, This drug can be used in combination with another drug including those selected from anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these drugs.

The invention discloses an anti-inflammation active component group of a stomatitis clearing preparation and an analysis method. Fingerprint characteristic spectra of the component group are constructed and are applied to detecting the quality of the stomatitis clearing preparation. The analysis method which is a quality detecting method particularly includes detecting the quality of the stomatitis clearing preparation by the aid of a detection index which is anti-inflammation efficacy; uniformly designing difference samples with different component proportions; acquiring fingerprint characteristic data of the difference samples by the aid of UFLC-Q-TOF-MS / MS (ultrafast liquid chromatography-quadrupole-time of flight-mass spectrometry / mass spectrometry) technologies; acquiring anti-inflammation activity data of the preparation. The relevance between chemical components of the difference samples and the efficacy is comprehensively analyzed by the aid of the mathematical statistics method, accordingly, 29 anti-inflammation efficacy active components can be determined, and the fingerprint characteristic spectra of the component group can be constructed. Compared with the prior art, the anti-inflammation active component group and the analysis method have the advantages that the active component group is analyzed on the basis of the relevance between the spectra and the efficacy, accordingly, the quality of raw medicinal materials, semi-finished products and finished products can be directly, objectively, scientifically and comprehensively monitored in production procedures, and the effectiveness and the quality consistency of the products can be guaranteed.

The present invention provides an excellent drug delivery system to posterior segments. An injection according to the present invention is a periocular injection which comprises fine particles containing a drug and enables the drug to deliver to the posterior segments. The drug can be efficiently delivered to the posterior segments (such as a retina, a choroid and an optic nerve) while scarcely injuring ophthalmic tissues by administering the fine particles containing the drug periocularlly. Preferred fine particles are made of a synthetic biodegradable polymer, their average particle diameter is 50 nm to 150 μm, and the drug is dispersed in the fine particles uniformly. Preferred drugs are anti-inflammatories, immunosuppressors, antivirals, anticancer drugs, angiogenesis inhibitors, optic neural protectants, antimicrovials and antifungal agents.

The invention provides methods of delivering pharmacologic agents linked to an internalization peptide, in which an inflammatory response inducible by the internalization peptide is inhibited by co-administration of an anti-inflammatory or by linking the internalization peptide to biotin or similar molecule. Such methods are premised in part on the results described in the examples whereby administration of a pharmacological agent linked to tat high dosages is closely followed by an inflammatory response, which includes mast cell degranulation, histamine release and the typical sequelae of histamine release, such as redness, heat, swelling, and hypotension.

Novel compounds and methods of using those compounds for the treatment of inflammatory conditions, hyperproliferative diseases, cancer, and diseases characterized by hyper-vascularization are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein, abl kinase protein, bcr-abl kinase protein, braf kinase protein, VEGFR kinase protein, or PDGFR kinase protein comprises the step of contacting said kinase protein with the novel compounds.

Disclosed are stable compositions comprising povidone-iodine and a steroid, and methods of making and using such compositions. Also disclosed herein are stable compositions comprising povidone-iodine and an NSAID, and methods of making and using such compositions.

A composition comprises plasmin or an enzymatically equivalent derivative thereof and at least an anti-inflammatory medicament. The composition can be used to effect or induce a controlled posterior vitreous detachment (“PVD”) to prevent, treat, or ameliorate a potential complication of a pathological ocular condition. Such a composition can be administered intravitreally.

Conductive formulations containing conductive agents, such as salts, ionic surfactants, or other substances that are in an ionized state or easily ionized in an aqueous or organic solvent environment, and methods of use, have been developed. One or more active agents, such as antivirals, antimicrobials, anti-inflammatories, proteins or peptides, may optionally be included with the formulation. The active agent may be administered with or incorporated into the formulation, or may be administered after the conductive formulation is administered. When applied to mucosal lining fluids, the formulation alters the physical properties such as the surface tension, surface elasticity, and bulk viscosity of the mucosal lining. The formulation is administered in an amount sufficient to alter biophysical properties in the mucosal linings of the body. The formulations may be administered for several different purposes: reducing the spreading of infectious diseases, both viral and bacterial, such as SARS, influenza, tuberculosis, and RSV in humans and hoof and mouth disease in cloven-tooted animals; minimizing ambient contamination due to particle formation during breathing, coughing, sneezing, or talking which is particularly important in the clean room applications; decreasing or preventing the occurrence of obstructive sleep apnea and some cases of irritable bowel syndrome; and controlling the uptake kinetics of drug molecules and pathogens.

The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.

The invention discloses a diterpenoid compound and the preparing method and application thereof. The diterpenoid compound is obtained by using aralia melanocarpa roots as the raw material through extractum extraction, organic solvent extraction, column chromatography on silica gel and high pressure liquid chromatography separation. The molecular formula of the diterpenoid compound is C20H30O3. The name of the diterpenoid compound is 14-oxygen-ent-8(9),15-(14-oxo-ent-pimara-8(9),15-diene-19-oic acid). The structural formula is as shown in the specification. According to the preparing method, aralia melanocarpa roots are used as the raw material, and extractum extraction, organic solvent extraction, column chromatography on silica gel and high pressure liquid chromatography separation are conducted to generate the diterpenoid compound. The diterpenoid compound can be applied to preparation of anti-inflammatory drugs for prevention and / or treatment. The diterpenoid compound is subjected to in-vitro anti-inflammatory activity testing, and experimental results show a good lipopolysaccharide (LPS) restraining effect and a good effect of inducting pulmonary alveolar macrophages (RAW264.7) to generate NO. A new compound or lead compound with high application value can be provided for the medical industry.

The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.

The invention belongs to the technical field of medicines and discloses new diarylheptanoid compounds extracted and separated from Guangxi curcuma zedoary and application thereof in the field of medicines. The chemical structure of the diarylheptanoid compounds is determined by spectrum technology such as a high resolution mass spectrum, one-dimensional and two-dimensional nuclear magnetic resonance spectrum and the like, and a chemical method. The diarylheptanoid compounds can be combined with a pharmaceutically acceptable carrier to prepare clinically acceptable medicines for anti-inflammatory treatment. Experiments for inhibiting lipopolysaccharide-induced rat macrophage from synthesizing nitric oxide (NO) in vitro prove that: the diarylheptanoid compounds have high activity of inhibiting the nitric oxide from being generated, and can be used as anti-inflammatory medicines for preventing and / or treating human and animals.

The present invention relates to a pharmaceutical composition for the prevention or treatment of immune disorders and inflammatory diseases, comprising stem cells that are generated by culturing stem cells expression Nucleotide-binding Oligomerization Domain protein 2 (NOD2) with a NOD2 agonist or a culture thereof. More particularly, the present invention relates to a method for suppressing immune responses or inflammatory responses of a subject, comprising the step of administering the pharmaceutical composition, the stem cells or culture thereof to the subject, a method for preparing an immunosuppressive drug or an anti-inflammatory drug using the stem cells or culture thereof, a method for preparing PGE2 or TGF-β1 comprising the step of culturing NOD2-expressing stem cells in culture medium with a NOD2 agonist, a graft comprising stem cells expressing NOD2 and the NOD2 agonist, a method for preparing the graft, a composite comprising stem cells expressing NOD2 and the NOD2 agonist, and a culture generated by culturing the NOD2-expressing stem cells with a NOD2 agonist.

The present invention relates to acetamido glucose derivatives of indomethacin and their synthesis process and use. The kinds of acetamido glucose derivatives of indomethacin prepared with indomethacin and acetamido glucose are 1-O-[1-(4-chloro-benzoyl)-5 -methoxy-2-methyl-3-indolyl-acetoxy]-2-acetylamino-2-deoxy-alpha-D-glucose and 6-O-[1-(4-chloro-benzoyl)-5-methoxy-2-methyl-3-indolyl-acetoxy]-2-acetylamino-2-deoxy-alpha-D-glucose. The derivatives of the present invention has the activity of inhibiting mouse ear dropsy caused by croton oil and may be used in preparing antiphlogistic medicine.

Methods and apparatus of providing a subject with post-operative, sustained-release of a biological agent within a synovial joint is disclosed. These methods involve securing a depot containing the biological agent to a ligament, tendon, muscle within the joint to provide sustained-release of the agent while allowing for normal joint articulation. This methodology may be utilized to provide for sustained-release of a biological agent useful in treating various traumas and disorders of the joint. Such biological agents include antagonists of inflammation-related proteins, such as TNF-α, IL-1β, IL-6, IL-8, NF-κB, High Mobility Group Box 1 (HMG-B1), IL-2, IL-15 and steroidal and non-steroidal anti-inflammatories. Other biological agents include anti-inflammatory cytokines such as IL-10, IL-4, IL-13, and TGF-β. The biological agents also include osteogenic and cartilage producing growth factors such as, but not limited to, BMP-2, BMP-4, BMP-6, BMP-7, BMP-8, and MIA CD-RAP. Finally, the biological agents include siRNA and / or therapeutic antibodies.

The invention relates to a drug-loaded mesoporous-silica-reinforced dental binder and a preparation method thereof. The binder comprises following components by weight: 40-60% of a resin component, 35-50% of a dilution component, 2-10% of an acid monomer, 0.2-0.5% of a photoinitiator, 0.1-0.3% of a promoter, a trace amount of a polymerization inhibitor and 1-10% of mesoporous silica. The binder has high strength and drug releasing property, and therefore the binder is advantaged by loading and performing controlled releasing of antibacterial agents, anti-inflammatory drugs, hemostatics, etc.. The binder not only has a binding function, but also has certain functions of treating and preventing bacterial infection, and can be used as a dentine binder in clinic.

The invention relates to an application of a tanshinone compound in preparing anti-tumor medicaments, and the prepared medicaments can resist tumors, such as brain tumors, lung cancer, liver caner, breast cancer, prostatic cancer, pancreatic cancer, cervical cancer, gastric cancer, esophagus cancer, and the like. Proved by experiments, the tanshinone compound is concentration-dependent to suppress the proliferation of tumor cells. The compound can obviously induce the expression of quinone reductase and obviously suppress the generation of tumor vessels, thus the compound can also be used for preparing cancer chemical prevention medicaments, anti-inflammatory medicaments and medicaments for suppressing the generation of the tumor vessels. Frequently used low-price reagents, such as alcohol, chloroform, methanol, silica gel, and the like, are used for separating tanshinone compound monomers from medicinal materials. The method is simple and reliable, has low cost and high efficiency, can be used for carrying out industrialized mass production and is beneficial to popularization and application. The tanshinone compound has a structural general formula disclosed in the specification.

The invention provides methods of delivering pharmacologic agents linked to an internalization peptide, in which an inflammatory response inducible by the internalization peptide is inhibited by co-administration of an anti-inflammatory or by linking the internalization peptide to biotin or similar molecule. Such methods are premised in part on the results described in the examples whereby administration of a pharmacological agent linked to tat at high dosages is closely followed by an inflammatory response, which includes mast cell degranulation, histamine release and the typical sequelae of histamine release, such as redness, heat, swelling, and hypotension.

The invention relates to an alginate-drug loaded nanoparticle-polycation microcapsule and preparation and application thereof. The microcapsule product is a spherical microcapsule with a particle sizeof 100 to 1000 microns. The structure of the microcapsule product is divided into two parts of a microcapsule membrane and an inner core. The microcapsule membrane is self-assembled layer by layer byalginate, drug-loaded nanoparticles and polycations to form a polyelectrolyte composite hydrogel film, and the inner core is a hydrogel or hydrosol environment containing animal cells. The microcapsule product is used as an immunosuppressive tool in embedding carriers for cell transplantation. Under the premise of ensuring the microcapsule strength and immuno-isolation performances, the surface roughness and surface charge of the microcapsule membrane can be reduced, the in-situ release of an anti-inflammatory drug on the surface of the microcapsule is realized, and the problem of fibrillation wrapping is solved from two aspects of stabilization of the microcapsule membrane by the drug-loaded nanoparticles and in-situ release of the anti-inflammatory drug for anti-inflammation.

The invention discloses a method for treating malignant tumors with joint medicament administration and also discloses an anti-malignant tumor medicinal composition with an antitumor activity and a low toxicity and an anti-malignant tumor medicinal preparation using the medicinal composition as an active component. The method comprises a step of jointing administrating anti-inflammatory medicaments, such as glucocorticosteroids or immunosuppressive agents or biotic agents of target cell factors and a carboxamidotriazole or derivatives or intermediates of the carboxamidotriazole as a medicamentto treat malignant tumors, wherein the anti-inflammatory medicaments have a certain regulation effect on cell factors. Tests prove that the combined medicament can increase the sensitivity of tumor cells to the carboxamidotriazole, so the combined medicament can be used as a broad-spectrum medicament for treating a plurality of malignant tumors, particularly non-small cell lung cancer, colon cancer and the like.

Pharmaceutical compositions are provided which comprise effective amounts of antimicrobials, anti-inflammatories, and antihistamines, to provide an ulcer medication which prevents secondary infections and promotes healing while providing immediate relief from pain. The composition may be used to treat a variety of ulcers including but not limited to intraoral aphthous ulcers and non-oral lesions.

Aspirin and phenol antioxidant p-hydroxyphenyl acrylic acid or ferulic acid are used as materials to prepare two kinds of antioxidant aspirin derivatives, named separately as 2-acetoxy-benzoic acid-2-[3-(4-acetoxy-phenyl)-acrylyloxy]-acetate and 2-acetoxy-benzoic acid-2-[3-(3-methoxy-4-acetoxy -phenyl)-acrylyloxy]-acetate chemically. The antioxidant aspirin derivatives are used in preparing antiphlogistic medicine.

The present invention relates to novel compounds and methods of use for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. In particular, methimazole derivatives and tautomeric cyclic thiones have the ability to inhibit the adhesion and the migration of leukocytes. In addition to being active anti-inflammatories, the methimazole derivatives and tautomeric cyclic thiones and their physiologically tolerable salts, derivatives and prodrugs are generally suitable for the treatment (i.e., for the therapy and prophylaxis) of diseases that are based on the interaction between VCAM-1 and its ligands or can be influenced by an inhibition of this interaction. In particular, the methimazole derivatives and tautomeric cyclic thiones are suitable for the treatment of diseases that are caused at least partly by an undesired extent of leukocyte adhesion and / or leukocyte migration or are connected therewith, and for whose prevention, alleviation or cure the adhesion and / or migration of leukocytes should be decreased.

The invention provides aminoquinazolinone and aminoisoquinolinone derivatives. Through multiple experiments, it is validated that the synthesized compounds have excellent PI3Kalpha and PI3Kgamma inhibition effects, and most of the compounds have a significant inhibition effect on PI3Kalpha, and show a potent growth inhibition effect on tumor cell lines such as a PIK3CA-mutated human breast cancercell line (MCF7). Therefore, the aminoquinazolinone and aminoisoquinolinone derivatives can be applied to preparing antitumor and anti-inflammatory drugs, and can be applied to drugs for the treatmentof human or animal cell proliferation-related tumors as a PI3Kalpha inhibitor. The drugs are prepared from any one or more of the derivatives, and pharmaceutically acceptable salt and solvate of thederivatives, and a pharmaceutically acceptable carrier. The general formulas a and b of the compounds are shown in the description.

The invention relates to ten 3,5-bis(arylidene)-N-benzenesulfonyl-4-piperidinone compounds having anti-tumor and anti-inflammatory activities, and belongs to the technical field of anti-tumor and anti-inflammatory medicines. A preparation method of the 3,5-bis(arylidene)-N-benzenesulfonyl-4-piperidinone compounds comprises the following steps: firstly, performing claisen-schmidt condensition reaction on 4-piperidinone hydrochloride and aromatic aldehyde to obtain a 3,5-bis(arylidene)-N-H-4-piperidinone hydrochloride intermediate product so as to further perform benzene sulfonylation on the 3,5-bis(arylidene)-N-H-4-piperidinone hydrochloride intermediate product and a sulfonylation reagent to obtain the 3,5-bis(arylidene)-N-benzenesulfonyl-4-piperidinone compounds. The compounds have good anti-tumor and anti-inflammatory activities, can avoid the genetic toxicity of currently-used anti-tumor medicines, have little toxicity to normal cells, and also have good anti-inflammatory activity.The preparation method is simple and convenient to operate, is mild in reaction conditions, is high in synthetic yield, and is beneficial for being widely popularized in anti-tumor and anti-inflammatory fields.